← Browse by Condition
Medical Condition
cll sll
Total Trials
2
Recruiting Now
2
Trial Phases
Phase 1, Phase 3
NCT04775745 Phase 1
Recruiting
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Enrollment
60 pts
Location
United States
Sponsor
Newave Pharmaceutical Inc
NCT06319456 Phase 3
Recruiting
A Global Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Enrollment
344 pts
Location
China
Sponsor
Ascentage Pharma Group Inc.